Application of emodin and combination of emodin and polydatin in treating metabolic syndrome

A technology for metabolic syndrome and emodin, which is applied in the application field of emodin and the combination of emodin and polydatin in the treatment of metabolic syndrome, and can solve the problems of no internal connection, single animal model factors, and lack of dynamic observation of detection indicators, etc.

Inactive Publication Date: 2019-02-22
孟凤仙 +1
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] Although polydatin has the effects of lowering blood sugar, blood fat, and uric acid in the prior art, it has the following defects: the animal model has a single factor in modeling, has no internal relationship with each other, and has a large difference from human diseases; the lack of detection indicators Dynamic observation; there is no internal connection between indicators, and the targets are scattered
[0015] To sum up, the combination of polydatin, emodin and polydatin in the prior art does not disclose that the combination of polydatin, emodin and polydatin acts on metabolic syndrome through the same signaling pathway, that is to say, there is no combination of polydatin, emodin and polydatin The combination of glycosides can simultaneously reduce the content of blood uric acid, blood sugar, urine sugar, blood cholesterol, blood triglyceride, blood homocysteine, blood creatinine, blood urea nitrogen and urine protein through the same signaling pathway.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of emodin and combination of emodin and polydatin in treating metabolic syndrome
  • Application of emodin and combination of emodin and polydatin in treating metabolic syndrome
  • Application of emodin and combination of emodin and polydatin in treating metabolic syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Embodiment 1: Emodin group, and the influence of emodin and Polygonum cuspidatum group on spontaneous type 2 diabetes mouse combined dyslipidemia model

[0035] Experimental materials and methods

[0036] 1. Animal model:

[0037] Spontaneous type 2 diabetic mice (KK-ay mice) combined with abnormal blood lipid metabolism model, SPF grade male 8-9 weeks old, body weight 30.94±1.67g, purchased from Beijing Huafukang Experimental Animal Technology Co., Ltd., license number SCXK (Beijing) 2009-0004. Six male C57BL / 6J mice, weighing 24.57±1.60 g, were purchased from Beijing Huafukang Experimental Animal Technology Co., Ltd., license number SCXK (Beijing) 2009-0007.

[0038] 2. Test drug:

[0039] Emodin: National drug standard substance, about 20mg package, batch number: 110756-200110 (National Institute for Food and Drug Control)

[0040] Polydatin: chemical reference substance, about 20mg package, batch number: 111575-200502 (National Institute for Food and Drug Cont...

Embodiment 2

[0076] Embodiment 2: the influence of emodin and emodin+polydatin on KK-ay mouse kidney histopathological changes:

[0077] 1. HE staining

[0078] In the model control group, glomerular lesions, renal tubular lesions, renal interstitial inflammatory infiltration, and the total score of lesions were all significantly increased, compared with the normal control group (P<0.1); emodin and emodin+polydatin were continuously After 12 weeks of administration, the glomerular lesions, renal tubular lesions, and renal interstitial inflammatory infiltration can be reduced to varying degrees within the tested dosage range, and the total lesion score can be reduced, which is significantly different from that of the model control group (P<0.1 ).

[0079] Table 5 Classification score of renal lesions in each group of emodin and emodin+polydatin

[0080]

[0081] Note: Compared with the normal group, #P<0.05; compared with the model group: *P<0.05.

[0082] Table 6 The total score of kid...

Embodiment 3

[0092] Example 3: Effects of emodin and emodin+polydatin on AMPK / iNOS / NF-κB signaling pathway in spontaneous type 2 diabetic mice with dyslipidemia model

[0093] 1. Tested drug: Emodin: National drug standard substance, about 20mg package, batch number: 110756-200110 (National Institute for Food and Drug Control)

[0094] Polydatin: chemical reference substance, about 20mg package, batch number: 111575-200502 (National Institute for Food and Drug Control)

[0095] Dose design:

[0096] High, medium and low doses of emodin: use distilled water to prepare large, medium and small doses of 13.33mg / (kg·d), 6.67mg / (kg·d), 3.33mg / (kg·d) respectively

[0097] High, medium and low doses of emodin + polydatin: take half the weight of emodin and polydatin respectively and prepare 13.33mg / (kg·d), 6.67mg / (kg·d), 3.33mg / (kg·d) with distilled water large, medium and small doses

[0098] 2. Experimental animals: SPF grade male KK-Ay mice aged 8-9 weeks, weighing (30.94+1.67) g, purchased ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of emodin and combination of emodin and polydatin in preparing a drug for treating metabolic syndrome, in particular to an application of modin and combinationof emodin and polydatin in preparing a drug for treating hyperuricemia, hyperlipidaemia, hyperglycemia, hyperhomocysteinemia and obesity. The drug can be prepared into clinically or pharmaceutically acceptable proper preparation such as troches, capsules, granules, water injections, powder injections, freeze-dried powder injections, sprays, suppositories, dropping pills and the like.

Description

technical field [0001] The invention relates to the application of emodin and combination of emodin and polydatin in treating metabolic syndrome. Background technique [0002] Metabolic syndrome refers to the pathological state in which the metabolism of proteins, fats, carbohydrates and other substances in the human body is disturbed, and it is a group of complex metabolic disorder syndromes. It has the following characteristics: ① A variety of metabolic disorders in one, including obesity, hyperglycemia, hypertension, dyslipidemia, high blood viscosity, high uric acid, high incidence of fatty liver and hyperinsulinemia, these metabolic disorders are heart, The pathological basis of cerebrovascular disease and diabetes, it can be seen that diabetes is not an isolated disease, but a component of metabolic syndrome; ②At present, obesity, especially central obesity, is believed to cause insulin resistance and hyperinsulinemia; and ③It can be Lead to a variety of diseases, suc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/122A61K31/7034A61P19/06A61P3/06A61P3/10A61P3/00A61P3/04
CPCA61K31/122A61K31/7034A61P3/00A61P3/04A61P3/06A61P3/10A61P19/06A61K2300/00
Inventor 孟凤仙崔晓兰王洁卜祥伟张正菊
Owner 孟凤仙
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap